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This study aimed to determine the effect of reducing the dietary linoleic acid (LA) intake 33 
from ~5% to <2.5% energy (%E) on n-3 long chain PUFA (LCPUFA) status in humans. 34 
Thirty-six participants followed a <2.5%E LA diet for 4 weeks. Nutrient intakes were 35 
estimated from diet diaries and blood samples were collected for assessment of fatty acid 36 
composition in plasma and erythrocyte phospholipids. LA intakes were reduced from 4.6%E 37 
to 2%E during the low LA intervention (P<0.001) while n-3 LCPUFA intakes were 38 
unchanged. LA and total n-6 PUFA content of plasma and erythrocyte phospholipids were 39 
significantly reduced after the low LA diet phase (P<0.001). The n-3 LCPUFA content was 40 
significantly increased in plasma phospholipids after the low LA diet compared to baseline 41 
(6.22% vs 5.53%, P<0.001). These data demonstrate that reducing LA intake for 4 weeks 42 





The fatty acid composition of the typical diet of Western countries, including Australia, has 46 
undergone a substantial shift over the past half-century. This shift has been driven primarily 47 
by the replacement of animal fats with plant-based oils and spreads in cooking, baking and 48 
processed food and has resulted in a significant decrease in the per capita intake of saturated 49 
fats and a three-fold increase in the intake of the omega-6 polyunsaturated fatty acid (n-6 50 
PUFA), linoleic acid (LA) [1, 2].  51 
 52 
The health impacts of this marked change in dietary fatty acid composition are unclear, 53 
however concerns have been raised that this substantial increase in LA intake could have 54 
negative impacts on cardiovascular and metabolic health [3, 4]. This suggestion is based on 55 
the biochemical properties of the n-6 PUFA, since the long-chain derivative of LA, 56 
arachidonic acid (AA), gives rise to pro-inflammatory and pro-thrombotic compounds [5], 57 
and the fact that high circulating concentrations of n-6 PUFA have been implicated in an 58 
increased risk of inflammatory and allergic conditions in epidemiological studies [6]. While 59 
data from humans directly linking increased LA intake and disease are lacking, data from the 60 
Sydney heart study recently published by Ramsden and colleagues provided the first evidence 61 
from a randomized controlled trial that a dietary intervention in which saturated fats were 62 
replaced by concentrated sources of  LA (as opposed to a mixture of n-6 and n-3 PUFA) was 63 
associated with an increased risk of death from coronary heart disease, raising renewed 64 
concerns about the impact of n-6 PUFA on human health [7].  65 
 66 
LA competes with the short-chain n-3 PUFA alpha-linolenic acid (ALA) for the enzymes 67 
required for conversion to their respective long-chain derivatives and for incorporation into 68 
the plasma membrane [8]. Consequently, high LA diets may limit the capacity of increases in 69 
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dietary n-3 PUFA intake to improve n-3 PUFA status [9]. Given that several bioactive 70 
mediators derived from n-3 LCPUFA are less potent in their inflammatory actions than their 71 
AA-derived analogs [10], and others actually have potent inflammation-resolving [11] or 72 
neuroprotective properties [12], this competition has the potential to contribute to negative 73 
health outcomes. 74 
 75 
Current strategies to improve n-3 LCPUFA status of the population have focused almost 76 
exclusively on increasing dietary n-3 LCPUFA intake, via increased consumption of oily fish 77 
or through fish oil supplementation [13]. However, many Australians struggle to achieve 78 
regular fish intake [14] and dwindling marine resources have raised questions about the long-79 
term sustainability of this approach [15]. Given the competition that exists between n-6 and 80 
n-3, it has been suggested that lowering the LA content of the diet has the potential to both 81 
limit the production of n-6 derived pro-inflammatory mediators and enhance the biological 82 
efficacy of n-3 LCPUFA consumed in the diet. However, the ubiquity of LA in the food 83 
supply, particularly in pre-prepared and take-away foods, makes any attempt to reduce the n-84 
6 PUFA intake of free-living humans challenging.  85 
 86 
We previously designed a low n-6 PUFA diet, in which we reduced the LA content of the diet 87 
from ~5% to ~2%E by replacing standard plant-based oils and spreads with low n-6 PUFA 88 
alternatives (Macadamia oil and butter), and limiting intake of processed and take-away 89 
foods which utilize high n-6 PUFA oils [16]. Importantly, we showed that the reduction in 90 
LA intake could be achieved while still adhering to the national dietary recommendations 91 
(The Australian Guide to Healthy Eating (AGHE) guidelines) [17] and maintaining a 92 
saturated fat intake of less than 10%E [16].  The aim of the present study was to determine 93 
whether following this low LA diet for a 4 week period would result in reduced n-6 PUFA 94 
6 
 
and increased n-3 LCPUFA content in plasma and erythrocyte phospholipids in healthy 95 
human subjects.  96 
 97 
PATIENTS AND METHODS 98 
Participants 99 
Participants were recruited using email advertisements and flyers, and interested individuals 100 
were screened by research staff for eligibility. The inclusion criteria were: BMI <35kg/m
2
 101 
and weight stable, aged 18-65yrs, able to eat >5 meals at home per week and not regularly 102 
consuming more than 2-3 fish meals per week. Exclusion criteria included taking high 103 
potency fish oil supplements (>3g/day EPA/DHA), gastric mal-absorption, vegetarian or 104 
vegan diet, pregnant or breastfeeding. All participants gave informed consent. This study was 105 
approved by the Human Research Ethics Committees of the University of Adelaide and 106 
University of South Australia. 107 
 108 
Study design 109 
This was an open-label clinical trial which consisted of a 2 week control phase, during which 110 
participants were instructed to continue their habitual dietary intake, followed by 4 weeks on 111 
the low LA diet. No details of the low LA diet were provided at enrolment in order to 112 
minimize the potential for this to influence dietary choices during the 2 week control phase. 113 
Importantly this study design allowed for each subject to act as their own control which is an 114 
important consideration in free-living intervention dietary studies given the potential for 115 
considerable variability in dietary intakes between individuals. Baseline demographic, dietary 116 
and medical information was collected at enrolment. 117 
 118 
Clinic Appointments 119 
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All participants attended clinic appointments at enrolment, after the 2 week control phase and 120 
at the completion of the 4 week dietary intervention. All appointments were conducted 121 
between 7:30am and 9:00am after an overnight fast of at least 12 hours. During the clinic 122 
appointments, weight and height were measured with participants in light clothing and 123 
without shoes, using a digital weighing scale (SALTER, Victoria, Australia) and a 124 
stadiometer (SECA, New South Wales, Australia) respectively and Body Mass index 125 
calculated (weight/height
2
). Fasting venous blood samples (8 ml) were collected at each 126 
clinic appointment. After collection, blood samples were centrifuged for 15 mins at 3500xg at 127 
4ᵒC to separate plasma and erythrocytes for subsequent analysis of fatty acids. 128 
 129 
Dietary Information 130 
All participants were asked to maintain a 3-day weighed food diary each week during both 131 
the control and dietary intervention periods. Instructions on completing the diary were 132 
provided at enrolment, and participants were instructed to record their dietary intake for 2 133 
week days and 1 weekend day in each week of the study. Electronic kitchen scales (SALTER 134 
1021, Victoria, Australia) and standard metric measuring cups (Décor Cook® Measuring 135 
Cups/Spoons, Victoria, Australia) were provided to participants to assist them in completing 136 
the weighed food diary. 137 
 138 
Low LA diet 139 
The low LA diet was based on the diet previously designed by our group [16] and aimed to 140 
achieve an LA intake of ~2%E  whilst maintaining saturated fat intake at <10%E and not 141 
altering the intake of n-3 LCPUFA. Participants were provided with Macadamia oil 142 
(Suncoast Gold Vitality
TM
 Macadamia oil, 1.24g LA/100g) and butter (Western Star
TM
 Butter, 143 
1.60g LA/100g) and were instructed to use these in place of their usual oils and spreads in 144 
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food preparation and cooking. Participants were also provided with a list of specific food 145 
types and brands to be avoided during the low LA diet phase (based on a cut-off level of <1g 146 
LA/100g and/or <1g LA/serving size of food product). To facilitate compliance, participants 147 
were provided with written materials identifying low LA alternatives for commonly 148 
consumed foods to assist them in making appropriate food choices when eating out or 149 
purchasing take away foods. A list of low LA recipes was also provided to participants. 150 
These resources were adapted from those produced for participants in a previous low n-6 151 
PUFA trial [18]. All participants were contacted by telephone, email or social networking 152 
media every 1-2 weeks for ongoing support and to monitor compliance with weighed food 153 
diaries and participants were encouraged to contact study staff at any time during the trial 154 
with any questions or concerns.  155 
 156 
Dietary analyses 157 
The diet diaries were analyzed for energy intake, macronutrient composition, and fatty acid 158 
content including LA, ALA and total n-3 LCPUFA, using the FoodWorks Program 159 
(FoodWorks 7 Professional Student, Xyris Software), which uses the latest AUSNUT 2007 160 
food composition tables. These were developed as part of the National Children’s Nutrition 161 
and Physical Activity Survey, which contains nutrient values for more than 4200 foods, 162 
beverages and supplements. The n-3 LCPUFA content of foods was obtained from the 163 
AUSNUT 2007 and Australian RMIT Fatty Acids database within the FoodWorks program 164 
and expressed as grams/day and percentage of total energy intake (%E). In cases where 165 
information on the LA and ALA content of specific foods was not available on the 166 
FoodWorks databases, the LA content of these foods was either estimated based on similar 167 




Fatty Acid Analyses 170 
The fatty acid composition of plasma and erythrocyte phospholipids was analysed using gas 171 
chromatography as described in detail previously [19]. Briefly, total lipids were extracted 172 
from plasma and erythrocytes with chloroform/isopropanol and chloroform/methanol (2:1 173 
v/v) [20]. Thin layer chromatography (TLC) on silica gel plates (Silica gel 60H; Merck, 174 
Darmstadt, Germany) was then used to separate the phospholipids from total lipid extracts. 175 
The lipid classes were visualised under UV light and the phospholipids were transferred into 176 
a vial containing 1% (v/v) sulphuric acid (H2SO4) in methanol. All phospholipids were 177 
transesterified with 1% (v/v) H2SO4 in methanol at 70°C for 3 hours. After the samples were 178 
cooled, the resulting fatty acid methyl esters (FAME) were extracted in n-heptane and 179 
transferred into 2ml chromatography vials containing 1 to 2 grains of anhydrous sodium 180 
sulphate (Na2SO4). FAME  were then separated and quantified by gas chromatography (GC) 181 
(Hewlett-Packard 6890, California, United States of America) using techniques described in 182 
detail elsewhere [21]. For statistical purposes, fatty acids at concentrations lower than the 183 
limit of detection (0.05%) were allocated a set value of 0.025% (half the limit of detection). 184 
All solvents used for extraction and separation contained 0.005% (w/v) of the antioxidant, 185 
butylated hydroxyanisol (BHA). All solvents used in this study were purchased from Ajax 186 
Firechem Pty Ltd (Auckland, NZ) or Chem-Supply (South Australia, Australia) and were of 187 
analytical grade. Unless specified otherwise, other chemicals and reagents were purchased 188 
from Sigma-Aldrich (Missouri, United States of America). 189 
 190 
Statistical analysis 191 
All data are presented as median and inter quartile range (IQR). Due to the small sample size 192 
and non-normal distribution of a number of dietary intake variables and erythrocyte/plasma 193 
fatty acids, data were analysed using non-parametric tests. Dietary intake, plasma and 194 
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erythrocyte phospholipids fatty acid composition data at baseline and after 4 weeks on the 195 
low LA diet were compared using the Wilcoxon signed-rank test for matched pairs. A P value 196 




Thirty-six healthy participants (male=12, female=24) were recruited to the study. Of these, 201 
three subjects withdrew from the study during the 2 week control phase before the low LA 202 
PUFA diet commenced, due either to an inability to provide a blood sample (n=1) or because 203 
of increased work commitments (n=2). A total of 33 participants completed the study, 204 
including one participant whose results were excluded due to incomplete dietary records 205 
being maintained by the participant. Therefore, the results from the remaining 32 participants 206 
were included in the final analysis. The baseline characteristics of the participants are shown 207 
in Table 1. There was no change in body weight or BMI after the 4 weeks on the low LA diet 208 
compared to weight at baseline (data not shown). 209 
 210 
Dietary data 211 
The mean dietary intakes of energy, macronutrients, n-6 and n-3 PUFA during the 2 week 212 
control phase and during the 4-week dietary intervention are presented in Table 2. 213 
Participants consumed significantly less total energy and total fat during the low LA diet 214 
phase compared to baseline (P<0.05). There was no significant difference, however, in the 215 
intake of carbohydrate or protein in either g/day or as a percentage of total energy between 216 




Dietary LA intake decreased from 4.6%E at baseline to 2%E during the low LA diet period 219 
(P<0.001). Dietary ALA intake also decreased significantly during the low LA intervention 220 
compared to baseline (P<0.001).  There was a small but significant increase in the intake of 221 
saturated fat as a percentage of energy during the low LA diet phase compared to baseline 222 
(P<0.05).  Importantly, there was no change in n-3 LCPUFA intake during the low LA 223 
intervention (Table 2).  224 
 225 
Plasma phospholipid fatty acid profile 226 
Median plasma phospholipid fatty acids at baseline and following 4 weeks on the low LA 227 
diet are presented in Table 3. After 4 weeks on the low LA diet, there was a significant 228 
decrease in both LA and total n-6 PUFA content of plasma phospholipids compared to the 229 
control period (P<0.001), but no change in their AA content. There was no change in the 230 
saturated fat content of the plasma phospholipids after the low LA intervention. The plasma 231 
phospholipid content of EPA (P<0.01), DPA (P<0.05), DHA (P<0.001) and total n-3 232 
LCPUFA (P<0.001) were all significantly increased after 4 weeks on the low LA diet (Table 233 
3). There was no difference in the ALA content of the plasma phospholipids after 4 weeks on 234 
the low LA diet (Table 3).  235 
 236 
Erythrocyte phospholipid fatty acid profile 237 
Median erythrocyte phospholipid fatty acids at baseline and following 4 weeks on the low LA 238 
diet are presented in Table 4. Consistent with the plasma phospholipids, after 4 weeks on the 239 
low LA diet, there was a significant decrease in both LA and total n-6 PUFA content of 240 
erythrocyte phospholipids compared to the control phase (P<0.001), but no change in AA 241 
content. However, in contrast to the plasma phospholipids, there was no difference in 242 
erythrocyte phospholipid concentrations of the n-3 LCPUFA, EPA, DPA or DHA following 243 
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the low LA dietary intervention (Table 4). Stearic acid (18:0) content in the erythrocyte 244 
phospholipids increased from 11.4% at baseline to 11.9% (P<0.05) after 4 weeks on the low 245 
LA diet. 246 
 247 
DISCUSSION 248 
This study has demonstrated that it is feasible to reduce LA intake in the diet from 4.6%E to 249 
2%E in free-living humans. This is only the second study to demonstrate that n-6 PUFA 250 
intakes can be reduced to this extent in an outpatient setting, and the first in which the 251 
intervention was based on a combination of dietary advice and provision of study oils and 252 
fats, without providing additional study foods.  The observed diet-induced reduction in the 253 
LA content of plasma and erythrocyte phospholipids without an accompanying decrease in 254 
AA content in either blood fraction in the present trial is consistent with previous findings 255 
[18, 22, 23]. Collectively, these results suggest that any positive effects of reduced LA intake 256 
on inflammatory pathways are unlikely to be mediated by a reduction in AA. It is possible, 257 
however, that lowering LA intake for a 4 week period was insufficient to elicit changes in 258 
AA content and that AA content would have decreased had the diet been continued for a 259 
more extended period.  260 
Lowering the LA content of the diet for a 4 week period did, however, significantly increase 261 
the EPA, DPA and DHA content in plasma, but not erythrocyte phospholipids. Importantly, 262 
this occurred in the absence of any increase in n-3 LCPUFA intake, and a reduction in the 263 
dietary intake of ALA. The finding of an increase in n-3 LCPUFA status after following a 264 
low n-6 LA diet is in agreement with the results of MacIntosh and colleagues who provided 265 
participants with a low n-6 PUFA diet for 12 weeks[18], and consistent with the hypothesis 266 
that high n-6 diets can limit uptake of dietary n-3 LCPUFA into tissues.  The finding that 267 
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plasma phospholipid n-3 LCPUFA increased despite a significant reduction in dietary n-3 268 
ALA suggests that enhanced incorporation of dietary n-3 PUFA/n-3 LCPUFA, rather than 269 
increased conversion from n-3 ALA, likely played the dominant role in increasing n-3 270 
LCPUFA status. This interpretation is supported by the finding that the ALA content of the 271 
plasma and erythrocyte phospholipids were not decreased following the 4 weeks on the low 272 
LA diet, despite the significant reduction in dietary ALA intake. 273 
In contrast to the effects in plasma, there was no change in EPA, DPA or DHA content of 274 
erythrocyte phospholipids after 4 weeks on the low LA diet in this study. This is consistent 275 
with the results of two previous 4-week Australian trials [22, 23], but differs from that of 276 
Macintosh and colleagues, who reported a 51% increase in EPA and 19% increase in DHA 277 
content in erythrocyte phospholipids following a low n-6 diet for 12 weeks [18]. Since 278 
erythrocytes have a longer half-life than plasma phospholipids, a 4 week period of dietary LA 279 
lowering may be insufficient to produce any changes in tissue n-3 status in erythrocyte 280 
phospholipids [24]. However, the difference in trial duration cannot completely explain the 281 
results, since MacIntosh et al found substantial increases in EPA and DHA content in 282 
erythrocytes after only 4 weeks that were similar in magnitude to those at 12 weeks 283 
(Ramsden, unpublished data).  Two key differences between the present study and the study 284 
conducted by MacIntosh et al may help explain these results; the Macintosh trial was 285 
conducted in a US population which had much higher LA intakes at baseline compared to our 286 
Australian population (7.4%E vs. 4.6%E), and the MacIntosh trial maintained baseline 287 
dietary n-3 ALA throughout the intervention phase while n-3 ALA intake decreased 288 
significantly in the present trial. As a result, reducing LA intake to approximately 2 %E in the 289 
US trial would be expected to produce a proportionally greater increase in n-3 LCPUFA 290 
status due to a more pronounced reduction in competition for esterification into membrane 291 
phospholipids and conversion of n-3 ALA to EPA and DHA. 292 
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The unintentional decrease in ALA intake in our trial was likely due to the fact that many key 293 
dietary sources of ALA (canola oil, nuts and seeds) are also relatively high in LA and were 294 
not permitted during the low LA dietary intervention.  In addition, the macadamia oil and 295 
butter that were used as substitutes for standard vegetable oils and spreads contain very low 296 
levels of ALA. This was avoided in the MacIntosh trial by providing a small amount of 297 
ground flaxseed to participants during the low n-6 dietary intervention in order to maintain 298 
average US ALA intake despite a reduction in high LA vegetable oils that are also major 299 
sources of n-3 ALA (e.g. canola, soy) [18].  300 
Limitations 301 
As with the majority of dietary studies, the accuracy of dietary recording is a potential 302 
limitation in the current trial. While weighed food records are generally regarded as one of 303 
the higher quality methods of dietary recording, the very act of asking people to record their 304 
dietary intake has the potential to alter their dietary choices, both as a result of social 305 
desirability bias and potential to favour foods that are easier to weigh/record [25]. However, 306 
the significant reduction in LA and total n-6 PUFA content of both the plasma and 307 
erythrocyte phospholipids following 4 weeks on the low LA diet provides evidence of good 308 
compliance with the diet regimen. The decrease in energy intake and small, but significant, 309 
increase in the intake of saturated fat as a percentage of energy during the low LA diet is not 310 
unexpected given the restrictions on take-away/processed foods and intake of plant/vegetable 311 
based oils, however the potential impact of these changes would need to be considered if a 312 
low n-6 LA diet were to be maintained longer term. This study was also designed to have 313 
each individual act as their own control, there was no parallel control group. The benefit of 314 
this design is that it eliminates the variation between individuals especially in regard to 315 
dietary intake. However, not having a control group is a limitation of this study and larger 316 
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randomised controlled trials with a control group need to be conducted in future 317 
investigations.  318 
 319 
Clearly, the magnitude of change in n-3 LCPUFA status in this 4-week trial is much less than 320 
achieved by directly supplementing the diet with n-3 LCPUFA. Therefore, the potential for 321 
low LA diets to provide a substitute for n-3 LCPUFA supplementation to raise n-3 LCPUFA 322 
status may be limited. However, recent evidence suggests that high n-6 LA intakes have the 323 
potential to produce negative health effects through the production of bioactive lipid 324 
mediators derived from n-6 LA (e.g. hydroperoxy- and hydroxy-fatty acids), i.e. independent 325 
of n-3 LCPUFA status [26-28]. It is therefore possible that low n-6 LA diets may be 326 
associated with clinical benefits in spite of relatively modest effects on n-3 LCPUFA status. 327 
For example, the bioactive n-6 LA metabolite leukotoxin is reported to contribute to tissue 328 
damage [29, 30], and the n-6 LA metabolites 9- and 13-HODE are reported to have pro-329 
nociceptive properties [31, 32]. Indeed, Ramsden and colleagues recently reported that a 330 
combined high n-3 plus low n-6 (H3-L6) dietary intervention reduced the severity of 331 
symptoms in chronic headache sufferers [33]. However, the relative importance of lowering 332 
dietary n-6 LA and increasing dietary n-3 PUFAs in producing the anti-nociceptive effects is 333 
not yet clear. In addition, the issue of sustainability of n-3 LCPUFA supplementation from 334 
marine sources has been called into question, and so there is a need to critically examine 335 
alternative strategies for maintaining/increasing n-3 LCPUFA status in the population. Thus, 336 
low n-6 PUFA diets may indeed have an important role to play in human health. 337 
 338 
CONCLUSIONS 339 
We have demonstrated that it is possible to reduce dietary LA intake to ~2%E in a free-living 340 
human population with no provision of foodstuffs apart from a highly monounsaturated oil 341 
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(macadamia oil) and butter, and without causing an increase in total fat intake. The low LA 342 
diet reduced LA and total n-6 PUFA content of plasma and erythrocyte phospholipids. 343 
Importantly, the low LA diet also increased the n-3 LCPUFA content of the plasma 344 
phospholipids, in the absence of any increase in n-3 LCPUFA intake, almost certainly due to 345 
higher incorporation of dietary n-3 LCPUFA. These data support the hypothesis that short-346 
term reductions in dietary LA intake have the potential to improve n-3 LCPUFA status, albeit 347 
modestly, without a need to increase dietary n-3 LCPUFA intake. We speculate that the 348 
magnitude of the increase in n-3 LCPUFA status would be greater by maintaining or 349 
increasing dietary ALA content and/or extending the intervention period beyond 4 weeks, 350 
and this remains an important avenue for further studies. In addition, it will be important to 351 
determine whether the biochemical changes identified in response to the low LA diet provide 352 
clinical benefits, particularly in conditions associated with increased bioactive derivatives of 353 
n-6 LA.  354 
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Table 1: Baseline characteristics of participants  
 Sample population 
Total number of participants (N) 32 
Gender 10 males; 22 females  
Age (years) Range:19-62; Mean ± SD: 31.5 ± 12.3 
BMI (kg/m
2











Dietary daily intake of energy, macronutrients and fatty acids during the control and low LA diet phase (median interquartile range) 
 Control Phase Low LA diet 
 
Total energy (kJ) 7852 (6509 - 9566) 6734 (5637 - 8374)* 
Protein (g) 82.0 (69.2 - 99.1) 81.4 (67.3 - 99.9) 
Carbohydrate (g) 205.7 (165.1 - 243.6) 196.7 (138.4 - 242.8) 
Total fat (g) 63.0 (51.3 - 83.8) 51.5 (42.1 - 64.5)* 
Monounsaturated fat (%E) 10.81(9.54-14.38) 11.76(9.23-14.33) 
Saturated fat (%E) 10.8 (8.1 - 12.7) 11.5 (9.5 - 13.8)* 
n-3 LCPUFA (mg) 235.0 (132.5 - 365.0) 215.0 (150.0 - 415.0) 
n-3 LCPUFA (%E) 0.12% (0.07 - 0.20) 0.15% (0.08 - 0.17) 
LA (g) 8.5 (6.6 - 13.6) 4.2 (9.5 - 13.8)* 
LA (%E) 4.6 (3.5 - 5.3) 2.0 (1.7 - 2.6)* 
ALA (g) 1.23 (0.81 - 1.68) 0.57 (0.45 - 0.81)* 
ALA (%E) 0.53 (0.44 - 0.81) 0.31 (0.27 - 0.38)* 
ALA, α-linolenic acid; LA, linoleic acid; * P<0.05 
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Table 3: Plasma phospholipid fatty acid profile at baseline and after 4 weeks on the low LA diet (median interquartile range).  
All results are expressed as a percentage of the total fatty acid in plasma phospholipids.  
 Baseline Week 4 
Monounsaturated fatty acids Total Mono 13.54 (12.66–14.60) 14.48 (13.13–15.39) 
 Oleic (18:1n-9) 10.15 (9.57–11.45) 10.98 (9.6–11.67) 
Saturated fatty acids Palmitic acid (16:0)  27.5 (26.9 – 28.1) 27.7 (26.7 – 28.7) 
 Stearic acid (18:0)  13.7 (12.9 – 14.1) 13.5 (12.7 – 14.1) 
n-6 PUFA LA (18:2n-6)  21.0 (19.2 – 22.5) 18.6 (17.3 – 21.2)*** 
 DGLA (20:3n-6) 3.05(2.64-3.44) 3.20(2.61-3.80) 
 AA (20:4n-6)  9.7 (8.6 – 11.0) 9.9 (9.5 – 11.3) 
 Total n-6 PUFA  35.1 (33.5 – 36.5) 33.7 (31.8 – 35.0)*** 
n-3 PUFA ALA (18:3n-3)  0.17 (0.14 – 0.23) 0.19 (0.15 – 0.22) 
 EPA (20:5n-3)  0.87 (0.80 – 1.18) 1.09 (0.83 – 1.34)** 
 DPA (22:5n-3)  0.88 (0.79 – 1.01) 0.95 (0.78 – 1.12)* 
 DHA (22:6n-3)  3.47 (3.01 – 3.90) 3.77 (3.33 – 4.26)** 
 Total n-3 PUFA  5.53 (5.04 – 6.56) 6.22 (5.57 – 6.69)*** 
LA, linoleic acid; DGLA, dihomo-gamma-linolenic acid; AA, arachidonic acid; ALA, α-linolenic acid; EPA, eicosapantaenoic acid; DPA, docosapantaenoic acid; DHA, 




Table 4: Erythrocyte phospholipid fatty acid profile at baseline and after 4 weeks on the low LA diet (median interquartile range).  
All results are expressed as a percentage of the total fatty acid in erythrocyte phospholipids. 
 Baseline Week 4 
    
Monounsaturated fatty acids Total Mono   
 Oleic (18:1n-9)   
 Stearic acid (18:0)  11.4 (10.9 – 12.3) 11.9 (11.2 – 12.6)* 
n-6 PUFA LA (18:2n-6)  10.6 (9.71 – 11.3) 9.41 (8.78 – 10.5)*** 
 DGLA (20:3n-6)   
 AA (20:4n-6)  13.4 (12.8 – 14.1) 13.3 (12.7 – 14.0) 
 Total n-6 PUFA  29.3 (28.7 – 30.9) 27.9 (27.2 – 28.7)*** 
n-3 PUFA ALA (18:3n-3)  0.14 (0.13 – 0.15) 0.12 (0.11 – 0.15) 
 EPA (20:5n-3)  0.76 (0.67 – 0.95) 0.82 (0.67 – 0.99) 
 DPA (22:5n-3)  2.43 (2.19 – 2.66) 2.40 (2.11 – 2.61) 
 DHA (22:6n-3)  4.67 (4.07 – 5.50) 4.64 (4.12 – 5.22) 
 Total n-3 PUFA  8.20 (7.67 – 8.87) 8.01 (7.60 – 8.66) 
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